Recent clinical trials have identified decreased autophagy markers such as elevated numbers of LC3‐II puncta and increased protein levels of p62 in liver of patients with steatosis or NASH (Gonzalez‐Rodriguez et al, 2014). This evidence concerns the gene MAP1LC3A and metabolic dysfunction-associated steatohepatitis.